AltMountain

AVSF - Cytovale 2023, LLC

Boston, MA · CIK 2008948
Status: no Form D since Jan 2024. Funds file a Form D when they begin selling and amend it each year while the offering continues, so this fund has most likely stopped raising money. It may still be investing, or it may have closed or been dissolved. The details below are from its latest filing, kept here as a record.

AVSF - Cytovale 2023, LLC is a venture capital fund based in Boston, Massachusetts. According to its most recent Form D, filed Jan 29, 2024, it has sold $1,192,250 of interests to 94 investors since its first sale in Jan 2024. The minimum investment it accepts from an outside investor is $5,000. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Michael Collins.

Total raised
$1,192,250Cumulative sales reported on Form D
Investors
94
First sale
Jan 15, 2024
Minimum investment
$5,000
Who can invest
Accredited investorsSection 3(c)(1): up to 100 beneficial owners
Offering exemption
Rule 506(b)No general advertising
Key people and entities
Michael Collins
Latest Form D
Jan 29, 2024

From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​​⁠

Questions about AVSF - Cytovale 2023, LLC

What is the minimum investment for AVSF - Cytovale 2023, LLC?

According to its latest Form D, filed Jan 29, 2024, the minimum investment AVSF - Cytovale 2023, LLC accepts from an outside investor is $5,000.

Who can invest in AVSF - Cytovale 2023, LLC?

AVSF - Cytovale 2023, LLC is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(b), which does not allow general advertising.

How much has AVSF - Cytovale 2023, LLC raised?

AVSF - Cytovale 2023, LLC reports $1,192,250 sold from 94 investors on its Form D filed Jan 29, 2024. This is cumulative sales since the offering began, not current assets or performance.

Where is AVSF - Cytovale 2023, LLC based?

AVSF - Cytovale 2023, LLC is based in Boston, Massachusetts.

When did AVSF - Cytovale 2023, LLC launch?

AVSF - Cytovale 2023, LLC reports its first sale in Jan 2024.

Size compared with every venture capital fund

Raised more than 66% of the 533 venture capital funds based in Massachusetts, and more than 64% of all 14,877 that report sales.

More venture capital funds in Boston

Similar-size venture capital funds in Massachusetts

All venture capital funds in Massachusetts